Neuroleptic malignant syndrome. amitriptyline, and thioridazine

Corrigan, F. M.; Coulter, F

doi:10.1016/0006-3223(88)90044-3

Cited by 20 publications

(12 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…; Mendhekar & Inamdar ). Other rare but potentially life‐threatening discontinuation syndromes reported in the published work include neuroleptic malignant syndrome (Amore & Zazzeri ; Corrigan & Coulter ; Kasckow et al . ; Margetic & Aukst‐Margetic ; May et al .…”

Section: Resultsmentioning

confidence: 99%

Antipsychotic discontinuation syndromes: A narrative review of the evidence and its integration into Australian mental health nursing textbooks

Salomon

Hamilton

2012

Int J Mental Health Nurs

View full text Add to dashboard Cite

In light of the high number of people discontinuing antipsychotics each year, it is essential that nurses develop a robust understanding of all aspects of the discontinuation experience. While there is a large body of published work documenting post-discontinuation relapse rates, less is known about other aspects of the discontinuation experience. This paper presents the results of a narrative review of international studies of antipsychotic discontinuation syndromes and their relevance to nursing practice. Four key mental health nursing textbooks used in student nurse education in Australia are examined to assess how this evidence has been incorporated into clinical recommendations. This review finds that the evidence for discontinuation syndromes could be more widely disseminated and applied than it is at present. Strikingly, this evidence has not been incorporated into key mental health nursing textbooks in Australia at all. Slow integration into nursing published work may be influenced by a number of clinical and research uncertainties. We consider the impact of this silence on key nursing roles of psycho-education and adverse event monitoring during antipsychotic discontinuation periods. Further robust research should be conducted into discontinuation syndromes as a matter of urgency. Given the high number of consumers potentially impacted upon by discontinuation syndromes, nurse authors and educators should consider revising key nursing textbooks to include the currently available information about discontinuation syndromes.

show abstract

Section: Resultsmentioning

confidence: 99%

Antipsychotic discontinuation syndromes: A narrative review of the evidence and its integration into Australian mental health nursing textbooks

Salomon

Hamilton

2012

Int J Mental Health Nurs

View full text Add to dashboard Cite

show abstract

“…Although the development of NMS after discontinuation of the neuroleptic medication is unusual, other case reports in the literature indicate that this may happen [17,27]. An additional impact of amitriptyline on the NMS in our patient cannot be completely excluded, as NMS under amitriptyline has been reported in the literature [6,19]. A weak argument against the impact of amitriptyline on the observed NMS could be that amitriptyline was reinitiated in combination with risperidone after remission of the NMS, and was tolerated well for more than five months.…”

Section: Discussionmentioning

confidence: 50%

Neuroleptic Malignant Syndrome due to Atypical Neuroleptics: Three Episodes in One Patient

Bottlender

Jäger²,

Hofschuster³

et al. 2002

Pharmacopsychiatry

View full text Add to dashboard Cite

Neuroleptic malignant syndrome (NMS) is a rare, but potentially lethal complication of antipsychotic medication. The risk of developing NMS under atypical neuroleptics seems lower than under typical neuroleptics. However, the use of atypical neuroleptics in modern psychopharmacotherapy is increasing, so the incidence of NMS under these drugs may also increase. Here, we will describe three episodes of NMS that fulfilled the DSM-IV criteria for NMS (APA, 1994). The epivodes of NMS occured under treatment with clozapine, risperidone, and amisulpride. These episodes had some atypical features that will be discussed with regard to the pathophysiological mechanisms leading to NMS.

show abstract

“…Thus overwhelming trauma, particularly in inescapable (61,75) Miller (83) proposes that MCS can be confirmed when, in a dean environmental medical unit (EMU), the following conditions are true: a) when a subject simultaneously avoids all chemical, food, and drug incitants, remission of symptoms occurs (unmasking); b) a specific constellation of symptoms occurs with reintroduction of a particular incitant; c) symptoms resolve when the incitant is again avoided; and d) with reexposure to the same incitant, the same constellation of symptoms reoccurs, provided the challenge is conducted within an appropriate window of time.…”

Section: Individual Ids Descriptionsmentioning

confidence: 99%

Section: Individual Ids Descriptionsmentioning

confidence: 99%

“…Some (4,75,113) may be initiators of kindling (4). This interference may also extend to polychlorinated biphenyls (PCBs) (75) and in general to organophosphate (OP) and organochlorine compounds (113). Some organochlorine insecticides such as chlorpyrifos reportedly cause both chronic neurologic symptoms (114) and modulation of the IRA (112).…”

Section: Individual Ids Descriptionsmentioning

confidence: 99%

See 1 more Smart Citation

Integrated Defense System Overlaps as a Disease Model: With Examples for Multiple Chemical Sensitivity

Rowat¹

1998

Environmental Health Perspectives

View full text Add to dashboard Cite

show abstract

Neuroleptic malignant syndrome. amitriptyline, and thioridazine

Cited by 20 publications

References 7 publications

Antipsychotic discontinuation syndromes: A narrative review of the evidence and its integration into Australian mental health nursing textbooks

Antipsychotic discontinuation syndromes: A narrative review of the evidence and its integration into Australian mental health nursing textbooks

Neuroleptic Malignant Syndrome due to Atypical Neuroleptics: Three Episodes in One Patient

Integrated Defense System Overlaps as a Disease Model: With Examples for Multiple Chemical Sensitivity

Contact Info

Product

Resources

About